T. Rowe Price Associates’s RxSight RXST Stock Holding History

T. Rowe Price Associates’s Portfolio RXST Stock Details RXST Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$242K	Buy	39,130 +7,374	+23%	+$61.2K	﹤0.01%	2767
2025 Q4	$331K	Sell	31,756 -1,772	-5%	-$17.8K	﹤0.01%	2601
2025 Q3	$302K	Buy	33,528 +10,426	+45%	+$91.5K	﹤0.01%	2603
2025 Q2	$301K	Buy	23,102 +5,354	+30%	+$80.5K	﹤0.01%	2526
2025 Q1	$449K	Buy	17,748 +1,564	+10%	+$46.5K	﹤0.01%	2290
2024 Q4	$557K	Sell	16,184 -23,863	-60%	-$1.08M	﹤0.01%	2246
2024 Q3	$1.98M	Buy	40,047 +2,840	+8%	+$146K	﹤0.01%	1642
2024 Q2	$2.24M	Sell	37,207 -23,701	-39%	-$1.35M	﹤0.01%	1500
2024 Q1	$3.14M	Buy	60,908 +994	+2%	+$48.8K	﹤0.01%	1369
2023 Q4	$2.42M	Buy	59,914 +34,003	+131%	+$997K	﹤0.01%	1437
2023 Q3	$724K	Buy	25,911 +622	+2%	+$18.5K	﹤0.01%	1945
2023 Q2	$730K	Buy	+25,289	New	+$563K	﹤0.01%	1963

Other funds holding RXST

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

Nomura Holdings Tokyo, Japan $37.7B AUM 34.44% 1-Year Est. Return

NSGL

No Street GP LP San Francisco, California $1.5B AUM 34.53% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return

T. Rowe Price Associates's RXST Position: Q1 2026 in Review

T. Rowe Price Associates increased its RxSight (RXST) stake by 23% in Q1 2026, buying an estimated $61.2K and bringing the position to 39,130 shares worth $242K. The position accounts for ﹤0.01% of the portfolio, ranked #2767.

T. Rowe Price Associates first reported a position in RXST in Q2 2023 and has held it in 12 quarters since. The position peaked at $3.14M in Q1 2024. 164 funds tracked by Wall St. Rank hold RXST as of Q1 2026.

T. Rowe Price Associates held 39,130 shares of RxSight worth $242K as of Q1 2026.
T. Rowe Price Associates bought 7,374 RxSight shares in Q1 2026, an estimated $61.2K.
RxSight made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q1 2026, its #2767 holding.
T. Rowe Price Associates first reported a position in RxSight in Q2 2023 and has held it in 12 quarters since.
T. Rowe Price Associates's RxSight position peaked at $3.14M in Q1 2024.
164 funds tracked by Wall St. Rank held RxSight as of Q1 2026.

Based on T. Rowe Price Associates's 13F filing for Q1 2026, filed 15 May 2026.